Post by
purse on Feb 13, 2018 10:46pm
Just a mater of time - Read last sentence
The Globe and Mail reports in its Tuesday edition that Canaccord analyst Neil Maruoka says Canopy Growth ($26.90) is "well-positioned to be a dominant global player." The Globe's David Leeder writes in the Eye On Equities column that Mr. Maruoka continues to rate the shares "hold." He elevated his share target to $26 from $18.50. Analysts on average target the shares at $29.94. Mr. Maruoka says in a note: "Never before have we witnessed burgeoning international markets with essentially no competition from U.S. industry (given currently restrictive federal legislation). As other countries seek to establish durable and stable cannabis infrastructure, we believe that Canadian companies are poised to take a leadership role through the export of both product and production know-how. We believe the most near-term and significant opportunity for Canadian LPs is the German medical market. However, other European markets are also emerging, and are increasingly attractive given high reimbursement and medical pricing. We believe this is important given the potential oversupply and commoditization of cannabis in Canada. Other near- and medium-term potential opportunities for Canopy include South America and Australia."
Comment by
HiGhRoLLeR420 on Feb 14, 2018 7:47am
Canadian LP’s (in my opinion), will end up monopolizing the entire global marijuana industry. And I still believe (again, my own opinion) that ICC will be scooped up by a major Canadian LP sometime this year. ICC have lots going in the right direction. If anyone can buy shares of ICC under $1.50, they will do alright! Happy investing!
Comment by
JohnnCash on Feb 14, 2018 9:33am
How about 1.63? hahaha..ha..ha..